Technical Analysis for ENTX - Entera Bio Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 2.22 | -3.06% | -0.07 |
ENTX closed down 3.06 percent on Wednesday, April 17, 2024, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 3
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Calm After Storm | Range Contraction | -3.06% | |
Upper Bollinger Band Walk | Strength | -3.06% |
Alert | Time |
---|---|
Possible Inside Day | about 4 hours ago |
Possible NR7 | about 6 hours ago |
60 Minute Opening Range Breakdown | about 7 hours ago |
Down 10% | about 8 hours ago |
Gap Down Partially Closed | about 9 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/03/2024
Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone (PTH) for hypoparathyroidism (EB612) and osteoporosis (EB613).
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Endocrine System Hormones Thyroid Osteoporosis Molecule Therapeutics Glands Hypoparathyroidism Parathyroid Hormone
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Endocrine System Hormones Thyroid Osteoporosis Molecule Therapeutics Glands Hypoparathyroidism Parathyroid Hormone
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.35 |
52 Week Low | 0.52 |
Average Volume | 262,364 |
200-Day Moving Average | 0.93 |
50-Day Moving Average | 1.51 |
20-Day Moving Average | 1.98 |
10-Day Moving Average | 2.30 |
Average True Range | 0.32 |
RSI (14) | 57.26 |
ADX | 49.43 |
+DI | 30.97 |
-DI | 14.54 |
Chandelier Exit (Long, 3 ATRs) | 2.38 |
Chandelier Exit (Short, 3 ATRs) | 2.27 |
Upper Bollinger Bands | 2.78 |
Lower Bollinger Band | 1.18 |
Percent B (%b) | 0.65 |
BandWidth | 81.21 |
MACD Line | 0.28 |
MACD Signal Line | 0.26 |
MACD Histogram | 0.0245 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.53 | ||||
Resistance 3 (R3) | 2.52 | 2.39 | 2.48 | ||
Resistance 2 (R2) | 2.39 | 2.31 | 2.40 | 2.46 | |
Resistance 1 (R1) | 2.31 | 2.26 | 2.35 | 2.32 | 2.45 |
Pivot Point | 2.18 | 2.18 | 2.20 | 2.19 | 2.18 |
Support 1 (S1) | 2.10 | 2.10 | 2.14 | 2.12 | 1.99 |
Support 2 (S2) | 1.97 | 2.05 | 1.98 | 1.98 | |
Support 3 (S3) | 1.89 | 1.97 | 1.96 | ||
Support 4 (S4) | 1.91 |